
24 June 2026Publication
Evolving health product & software risks
Discover how new EU reforms impact liability and recall risks for health products, software and AI - plus practical tips to navigate evolving legal challenges
Regulatory risk has become one of the key business concerns for corporates and financial institutions with its potential for direct damage both to a company’s financial well-being and to its brand or reputation. Investigatory powers have become more draconian and regulators are better funded. Criminal sanctions are more common-place and personal liability is imposed on directors and senior managers.
Simmons & Simmons has one of the leading regulatory practices in Europe and Asia with expertise in each of our core sectors: asset management & investment funds, financial institutions, life sciences and technology, media and telecommunications (TMT) .
We are one of the very few firms that has the expertise to advise on the full spectrum from the detail of compliance with technical requirements under industry rules, through to investigations and, in extreme cases, to criminal liability.
Advising clients which include both major financial institutions or companies and government departments or regulators gives us a valuable perspective and insight not widely available.
The ability to provide this breadth of advice across our network of offices in Europe, the Middle East and Asia makes our practice stand out from our competitors.
Advising Civil Aviation Authority in connection with judicial review proceedings initiated by easyJet concerning the Authority's decision in setting the price cap for charges at London Gatwick from 2008 to 2013.
Representing Dura Vermeer, one of the largest Dutch building companies, in its appeal to the General Court in the Dutch bitumen cartel case.
Acting for a major Japanese pharmaceutical company on the regulatory, commercial and trade mark aspects of an agreement following the citation by the EMA’s Invented Name Review Group of a marketed product with a similar name, as a cross-border team through our Tokyo, London and Milan offices.
If you have any questions, contact a member of the Regulation team for assistance:

24 June 2026Publication
Discover how new EU reforms impact liability and recall risks for health products, software and AI - plus practical tips to navigate evolving legal challenges

24 June 2026 Publication
Discover the essentials of the EU Pharma Package reform: key changes in protection, market access, supply, IP, advertising, digitalisation and policy.

09 June 2026 Publication
CSSF sets out enhanced expectations on valuation frameworks for illiquid assets, focusing on governance, models, controls and risk-based approaches for IFMs
_11zon.jpg?width=380&width=380&format=webply&auto=webp)
09 June 2026 Publication
The FCA has publishes a new webpage, setting out an update on proposed reforms to the UK MMF Regulation

09 June 2026 Publication
A summary of the Central Bank of Ireland's Markets Update No 8 of 2026 for regulated firms and other market participants